Anthera Announces First Quarter 2013 Financial Report and Conference Call

  Anthera Announces First Quarter 2013 Financial Report and Conference Call

PR Newswire

HAYWARD, Calif., May 3, 2013

HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH), a biopharmaceutical company focused on developing and
commercializing products to treat autoimmune diseases, will release its first
quarter 2013 financial report after market close on Monday, May 13^th. Anthera
will host a Corporate Update conference call on May 20^th, 2013.

Conference Call Access:
Date: Monday, May 20^th, 2013
Time: 5:00 pm Eastern Time

Domestic Dial-in: (877)312-8807
International Dial-in: (253)237-1190
Conference ID: 64577060

To access the 24-hour audio replay, U.S. and Canadian participants may dial
(855)859-2056; international participants may dial (404)537-3406. The
conference ID for the replay is 64577060. The audio replay will be available
until May 27^th, 2013.

About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on
developing and commercializing products to treat autoimmune diseases.
Anthera's Phase 3 development product candidate, blisibimod, targets elevated
levels of B-cell activating factor, or BAFF, which has been associated with a
variety of B-cell mediated autoimmune diseases, including systemic lupus
erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus
nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia
purpura, and others.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or
510-856-5598.

SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com